Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 10/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 10/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 4/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22231137 | 1.00 | CSNK2A2 (0.43) | CSNK2A2CSNK2BCSNK2A1ABCC1ABCG2 | |
| SCHEMBL22231422 | 1.00 | CSNK2A2 (0.43) | CSNK2A2CSNK2BCSNK2A1ABCC1ABCG2 | |
| SCHEMBL24605947 | 0.91 | CSNK2A2 (0.44) | CSNK2A2CSNK2BCSNK2A1ABCC1ABCG2 | |
| SCHEMBL22230865 | 0.90 | ABCB1 (0.50) | CSNK2A2CSNK2BCSNK2A1ABCC1ABCG2 | |
| SCHEMBL28619630 | 0.87 | CSNK2A2 (0.42) | CSNK2A2CSNK2BCSNK2A1ABCC1ABCG2 | |
| SCHEMBL22245081 | 0.86 | CSNK2A2 (0.41) | CSNK2A2CSNK2BCSNK2A1ABCC1ABCG2 | |
| SCHEMBL22231445 | 0.86 | CSNK2A2 (0.39) | CSNK2A2CSNK2BCSNK2A1ABCC1ABCG2 | |
| SCHEMBL22231472 | 0.86 | CSNK2A2 (0.39) | CSNK2A2CSNK2BCSNK2A1ABCC1ABCG2 | |
| SCHEMBL22231443 | 0.86 | CSNK2A2 (0.39) | CSNK2A2CSNK2BCSNK2A1ABCC1ABCG2 | |
| SCHEMBL22230858 | 0.85 | CYP1A1 (0.52) | CSNK2A2CSNK2BCSNK2A1ABCC1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911413-B1 | SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2023-12-06 | — | — | EP | claimed |
| US-20220213049-A1 | SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-07-07 | — | — | US | claimed |
| EP-3911413-A1 | SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-11-24 | — | — | EP | claimed |
| CN-113301959-A | Substituted chromen-4-ones for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2021-08-24 | — | — | CN | claimed |
| WO-2020148354-A1 | SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2020-07-23 | — | — | WO | claimed |
| EP-3911413-B1 | SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2023-12-06 | — | — | EP | disclosed |
| US-20220213049-A1 | SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220213049-A1 | SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-07-07 | — | — | US | disclosed |
| EP-3911413-A1 | SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-11-24 | — | — | EP | disclosed |
| CN-113301959-A | Substituted chromen-4-ones for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2021-08-24 | — | — | CN | disclosed |
| WO-2020148354-A1 | SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020148354-A1 | SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213049-A1 | SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP26B1, CYP7A1 | CSNK2A2 1452/4885CSNK2B 1017/4885CSNK2A1 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.